Aura Biosciences (AURA) announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors, effective March 31, 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AURA:
- Aura Biosciences Inc: Promising Clinical Progress and Financial Stability Justify Buy Rating
- Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress
- Aura Biosciences price target lowered to $19 from $21 at Citizens JMP
- Aura Biosciences Reports Progress in Cancer Trials
- Aura Biosciences price target raised to $25 from $22 at H.C. Wainwright